[Analysis of efficacy and safety of BCMA chimeric antigen receptor T cells in the treatment of 5 patients with recurrent/refractory IgD multiple myeloma]

Zhonghua Xue Ye Xue Za Zhi. 2023 Dec 14;44(12):1035-1037. doi: 10.3760/cma.j.issn.0253-2727.2023.12.012.

[Article in Chinese]

Authors

Y C Jia¹, X X Wang¹, W T Qiang¹, J Liu¹, P Guo¹, J Lu¹, X Q Fan¹, H Y He¹, J Du¹

Affiliation

¹ Department of Hematology, Myeloma & Lymphoma Center, Second Affiliated Hospital of Navy Medical University, Shanghai 200003, China.

PMID: 38503529
PMCID: PMC10834868
DOI: 10.3760/cma.j.issn.0253-2727.2023.12.012

No abstract available

MeSH terms

B-Cell Maturation Antigen
Humans
Immunotherapy, Adoptive
Multiple Myeloma* / therapy
Neoplasm Recurrence, Local
Receptors, Chimeric Antigen*
T-Lymphocytes

Substances

Receptors, Chimeric Antigen
B-Cell Maturation Antigen

Grants and funding

基金项目：国家自然科学基金（82170198）